[Overview] Yangtze River's 2 billion injections make another city and Pfizer loses half of the country

Wonderful content

A few days ago, the official website of the State Food and Drug Administration showed that the supplementary application of Parecoxib Sodium for injection from Guangzhou Hairui Pharmaceuticals of Yangtze River Pharmaceutical Group was approved.
Prior to this, one product regulation was approved for supplementary application.
Comment
.

July 30, 2021, the drug approval document pending information is released

According to data, Parecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor, developed by Pharmacia (now Pfizer) and listed in China in 2008
.

Sales of parecoxib sodium for terminal injection in public medical institutions in China in recent years (unit: 100 million yuan)

Source: Terminal competition landscape of China's public medical institutions

According to data from Meinenet, in recent years, the sales of parecoxib sodium for terminal injection in urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly, and after exceeding 1 billion yuan in 2018 , To break through the 2 billion mark in 2020
.

Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

At present, more than 20 manufacturers of parecoxib sodium for injection have been evaluated.
Among them, Chengdu Yuandong Biopharmaceutical, Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceutical, Zhengda Tianqing Pharmaceutical Group, Hunan Kelun Pharmaceutical and other companies have Supplementary applications have been approved and reviewed; China Resources Double-Crane Pharmaceutical, Chengdu Baiyu Pharmaceutical, Kunyao Group and other companies have been approved for generic 4 categories, which are deemed to have been reviewed
.

Source: official website of the State Food and Drug Administration, Mi Nei.